SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

A sharp selloff in semiconductor and AI-related stocks has traders focused on concerns that data-center approvals and construction could slow, particularly in Texas, weighing on future memory demand. The community is divided between seeing the decline as evidence of fading AI-investment momentum and viewing the policy fears as overblown, with some calling MU oversold after strong results and guidance.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovins strong third-quarter results, upbeat fourth-quarter outlook and expanded share-buyback authorization sparked a sharp rebound, with traders celebrating the results and speculating about a short squeeze. Others caution that the rally may fade, pointing to a slower growth outlook, rising AI costs and valuation concerns.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly results sparked debate: traders focused on weaker-than-expected daily-user growth and soft advertising trends, which weighed on the shares despite improved profitability and a positive outlook. Some viewed the selloff as an overreaction to stronger cash generation and guidance, while others saw user declines as a concern for future ad growth.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Concern that election results and local opposition could slow U.S. data-center expansion is weighing on Sandisk and other memory and AI-chip stocks. Traders are split between arguing that data-center demand will shift locations rather than disappear and warning that delays could pressure memory demand and pricing.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a selloff across AI neocloud stocks as traders weigh whether Democratic election gains and local opposition could slow data-center permitting and expansion. Bears see added execution and revenue-delay risks, while bulls argue Nebiuss global footprint and limited Texas exposure make the sector-wide fears overstated.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Democratic control of Congress has raised trader concerns about tighter AI and data-center regulation or permitting delays, weighing on Nvidia and semiconductor shares even as much of Big Tech rose. The community is split between fears of slower AI capital spending and the view that demand and data-center construction will continue or shift elsewhere.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms quarterly report is driving discussion: a modest earnings beat and stronger revenue outlook were overshadowed by handset weakness and warnings that rising memory and manufacturing costs could pressure margins, prompting a sharp after-hours selloff. Traders are split between concerns that phone-chip declines will persist and hopes that growth in automotive, IoT, data center chips, and the SpaceX partnership can diversify the business.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires Q3 results are driving attention: a revenue shortfall and post-earnings selloff have drawn criticism, while traders point to improved gross margins, a record backlog, and reaffirmed guidance as signs of progress. The debate centers on whether those operational gains outweigh the revenue miss and concerns about execution and possible dilution.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is drawing attention after a strong Q3 report and another increase to its 2026 outlook, alongside an initial 2027 forecast. Traders largely praised the growth and execution, while some questioned whether the projected growth pace supports the valuation; short-squeeze speculation is also circulating.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCrysts quarterly earnings beat and raised full-year revenue outlook are driving attention, but the stocks weak reaction has frustrated investors. Traders debate whether the unchanged ORLADEYO outlookdespite growth in the commercial businesssignals softer near-term sales, while others point to competition, debt and delayed pipeline catalysts as reasons the market remains cautious.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ZVRA There have been 2 cases that has been bringing some negative sentiment on Zevra’s Miplyffa.
1. The EMA FORMAL Refusal which is a big setback for gaining approval in EU and will  now probably take 5+ years for Miplyffa to reach full commercial launch in Europe because EMA approval for Miplyffa (arimoclomol) during the current re-examination process is very low. However,  Zevra will be able to continue establishing robust US commercial dominance and maintaining its European Expanded Access Program preserving patient share and goodwill, preventing competitor displacement while European regulatory hurdles are addressed.
2. Approval Prospects for Trappsol Cyclo
If Trappsol Cyclo achieves FDA approval, the impact on Zevra is low to moderate and may actually be positive for several key reasons: Complementary Mechanisms &amp; Combination Potential. In ultra-rare diseases, non-competing mechanisms often evolve into combination regimens rather than strictly replacing one another.

Mike Long

Sanford Webb

lance

Craig P.

Organic Blueberries

StockTwits for iOS

Zevra Therapeutics Inc

 There have been 2 cases that has been bringing some negative sentiment on Zevra’s Miplyffa.
1. The EMA FORMAL Refusal which is a big setback for gaining approval in EU and will  now probably take 5+ years for Miplyffa to reach full commercial launch in Europe because EMA approval for Miplyffa (arimoclomol) during the current re-examination process is very low. However,  Zevra will be able to continue establishing robust US commercial dominance and maintaining its European Expanded Access Program preserving patient share and goodwill, preventing competitor displacement while European regulatory hurdles are addressed.
2. Approval Prospects for Trappsol Cyclo
If Trappsol Cyclo achieves FDA approval, the impact on Zevra is low to moderate and may actually be positive for several key reasons: Complementary Mechanisms & Combination Potential. In ultra-rare diseases, non-competing mechanisms often evolve into combination regimens rather than strictly replacing one another.

Christopher Gaudet

NPC is complex and polygenic in its downstream damage. Miplyffa works intracellularly via heat shock proteins, whereas Trappsol works directly by clearing cyclodextrin-encapsulated lipids.
2. Administration Route Advantage: Miplyffa is an oral capsule, making it significantly less invasive than Trappsol, which requires continuous bi-weekly intravenous (IV) infusions. For pediatric populations, oral delivery provides a strong moat for adherence and preference.
3. Commercial Headstart: Miplyffa is currently established in the US market as an approved, first-line therapy. Even under an accelerated timeline, Trappsol would not enter the market until late 2027 or 2028, giving Zevra ample time to capture and entrench the addressable patient base.

While a second drug entrant splits nominal market share, it also expands overall diagnosis rates and commercial market size for NPC. Because Trappsol’s data showed its strongest efficacy on top of background therapy, a Trappsol approval may ultimately position Miplyffa as a foundational pillar of multi-drug combination therapy, rather than displacing it

@gauC26 Is this the RDL drug that recently failed without Miglustat?

 Is this the RDL drug that recently failed without Miglustat?

Corey Vaughn

@gauC26 The FDA also hates foreign based clinical trials as someone pointed out.  They essentially ignore those data points or heavily discount them.

 The FDA also hates foreign based clinical trials as someone pointed out.  They essentially ignore those data points or heavily discount them.

@gauC26 wtf are you talking about? There is no negative sentiment on Zevra. According to who, you? Wall Street? Does your opinion or Wall Street’s opinion have any bearing on the sentiment of the company itself? The EMA situation is what it is, and we will soon find out more. Why are you trying to create an imaginary 5+ year problem that doesn’t even exist today? Have you ever purchased a lottery ticket in your life? Why would you have done that if the odds are very low that you were going to win. By the way, Zevra has way better odds of EMA approval upon reevaluation than that lottery ticket you purchased in the past. Now what this this FUD you are trying to spread about Trappsol? Gtf off my board. Blocked.

 wtf are you talking about? There is no negative sentiment on Zevra. According to who, you? Wall Street? Does your opinion or Wall Street’s opinion have any bearing on the sentiment of the company itself? The EMA situation is what it is, and we will soon find out more. Why are you trying to create an imaginary 5+ year problem that doesn’t even exist today? Have you ever purchased a lottery ticket in your life? Why would you have done that if the odds are very low that you were going to win. By the way, Zevra has way better odds of EMA approval upon reevaluation than that lottery ticket you purchased in the past. Now what this this FUD you are trying to spread about Trappsol? Gtf off my board. Blocked.